Format

Send to

Choose Destination
BMC Cancer. 2019 Apr 11;19(1):345. doi: 10.1186/s12885-019-5523-6.

Clinical application of ultrasound-guided percutaneous microwave ablation for benign breast lesions: a prospective study.

Author information

1
Department of Ultrasound, Beijing Tian Tan Hospital, Capital Medical University, No. 119, West Road of South 4th Ring Road, Fengtai District, Beijing, 100160, China.
2
Department of Ultrasound, Affiliated Hospital of Guilin Medical University, Guilin, China.
3
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
4
Department of Ultrasound, The 3rd Affiliated Hospital of Guangxi Medical University, Nanning, China.
5
Department of Thyroid and Breast Surgery, The 3rd Affiliated Hospital of Guangxi Medical University, Nanning, China.
6
Department of Ultrasound, Beijing Tian Tan Hospital, Capital Medical University, No. 119, West Road of South 4th Ring Road, Fengtai District, Beijing, 100160, China. ttyyus@sina.com.

Abstract

BACKGROUND:

Background: Benign breast lesions are the most common diseases in adult women, which have been treated with minimally invasive therapies in recent years. Little is known about the feasibility of Microwave ablation (MWA) for benign breast lesion treatment. The primary aim of this prospective study was to evaluate the safety and efficiency of MWA as a potential therapeutic option for benign breast lesions in a single-center cohort study.

METHODS:

Women with possibly benign breast lesions based on an ultrasound (US) assessment who were scheduled to undergo MWA between November 2014 to July 2018 were included in the study. The patients underwent conventional US to measure the size of the lesion, Doppler US to assess the vascularity of the lesion, elastography to evaluate the stiffness of the mass, core needle biopsy of suspicious lesions, contrast-enhanced US to help determine the treatment plan and eventually MWA of the lesion. Lesions were followed at one, three, six, twelve and eighteen months after treatment to with the same imaging modalities.

RESULTS:

A total of 314 women aged 17 to 69 years old (mean = 36.9 ± 9.9 years) with 725 benign breast lesions (mean of maximum diameter = 10.86 ± 5.40 mm) were included. The frequency of palpable mass, pain and nipple discharge significantly decreased after treatment. Complete ablation rate was 97.8%, immediately after ablation, which increased to 100% after supplementary ablation of the 15 cases with incomplete ablation. Blood flow classification and lesion's volume also showed a significant decrease, while both volume reduction ratio and disappearance rate significantly increased following treatment. The elasticity score of the lesions showed fluctuations across different follow-up intervals. None of the patients experienced major complications and the 1% who had mild symptoms were successfully treated.

CONCLUSION:

MWA treatment is shown to be safe and efficient and has the potential to be considered as an alternative first line treatment for benign breast lesions.

KEYWORDS:

Benign breast lesion; Efficiency; Microwave ablation; Safety

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center